The National Bleeding Disorders Foundation (NBDF) is excited to announce a new accredited educational opportunity for healthcare providers. This live/virtual program will focus on optimizing non-factor replacement therapy for hemophilia patients.…
Pfizer recently provided new clinical trial updates for their investigational therapy marstacimab. The data was presented last month at the 2024 annual meeting of the European Hematology Association (EHA) in Madrid. Marstacimab is a…
MASAC meetings are in person and open to the public. However, we do understand all interested parties might not be able to attend. In an effort to keep everyone informed of the proceedings, the minutes from each meeting will be posted here.
MASAC MeetingMarch 8, 2024Washington, DC Call to Order Dr. DunnDr. Dunn called the meeting to order at 8:01 AM. Members approved…
For Immediate Release CONTACT: Kyla Clark National Bleeding Disorders Foundation 347-920-0047kclark@bleeding.org NBDF Unveils THRIVE Campaign: Empowering Individuals with Bleeding Disorders…
The 2024 Red Tie Soiree was a resounding success! Thanks to the generosity of our supporters, we raised over $215,000 to support vital research, treatment, and care for those affected by bleeding disorders. The evening was filled with…
Elevating Research with Community Voices: How Lived Experiences Drive Progress in Bleeding Disorders
Date: Wednesday, August 7, 2024 Time: 2:00 PM - 3:00 PM Location: Zoom (Registration Preferred) NBDF's Wednesday Webinar SeriesJoin us for an insightful…
Government Relations Update – July 2024FederalBiden Leaves the Race, VP Harris the Likely Candidate: On July 21, President Biden announced his decision to remove himself from the 2024…
Pfizer has announced positive topline results from their phase 3 clinical study of giroctocogene fitelparvovec, the company’s investigational hemophilia A gene therapy. The clinical trial program, known as AFFINE, is…